Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Nat Commun · 2023 · PMC10366102 · PMID 37488191

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Levels of pCDK1/2/3 in tumors also showed a reduction, although this did not reach statistical significance, possibly due to high variability of this marker at baseline (Supplementary Table 11 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.